ViroGates’ current and previous financial results, reports, analyst presentations, IPO documents, and more, are listed below.
Half-Year Report, H1 2023
Previous Interim/Half-Year Reports
Annual Report 2022
We are proud of our achievements in 2022, despite still operating in uncertain market conditions. We reached record sales levels in ViroGates’ history, with a net revenue of 10.2 DKK million. We created a sales uptake of suPARnostic® products for use in assessing the severity of COVID-19 patients, despite COVID-19 variants becoming milder and hospitalizations decreasing all over Europe. We worked proactively to explain the value of using our products more broadly in acute care triage, both to new and existing customers. In 2023, we will continue the effort towards converting our COVID-19 customers to emergency department use. We currently experience that the value of a clinical customer is too low, and we need to address this issue in 2023. We do look very much forward to the commercial launch of our newly developed product suPARnostic® POC+.
25 March 2022:Market Focus Update by Västra Hamnen Corporate Finance
18 November 2021:Market Focus Update by Västra Hamnen Corporate Finance
6 November 2020:Analyse af ViroGates A/S by Aktieinfo
27 October 2020:Market Focus Update by Västra Hamnen Corporate Finance
14 August 2020:Market Focus Update by Västra Hamnen Corporate Finance
30 March 2020: Market Focus Update by Västra Hamnen Corporate Finance
29 January 2020: Market Focus Initial Research by Västra Hamnen Corporate Finance
12 April 2019:Analyse af ViroGates A/S by Aktieinfo
4 October 2018:Analyse af ViroGates A/S by Aktieinfo
IPO 2018 Documents
11 June 2018: Presentation at Aktiespararnas Småbolagsdag in Stockholm